PMC:7205724 / 22333-23259
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 772 | 55-63 | Species | denotes | patients | Tax:9606 |
| 773 | 18-29 | Chemical | denotes | Tocilizumab | MESH:C502936 |
| 774 | 40-51 | Disease | denotes | lung injury | MESH:D055370 |
| 775 | 89-97 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 788 | 270-273 | Gene | denotes | IL6 | Gene:3569 |
| 789 | 453-456 | Gene | denotes | CRP | Gene:1401 |
| 790 | 120-128 | Species | denotes | patients | Tax:9606 |
| 791 | 246-254 | Species | denotes | Patients | Tax:9606 |
| 792 | 514-522 | Species | denotes | patients | Tax:9606 |
| 793 | 211-222 | Chemical | denotes | Tocilizumab | MESH:C502936 |
| 794 | 310-321 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 795 | 387-393 | Chemical | denotes | oxygen | MESH:D010100 |
| 796 | 581-592 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 797 | 134-142 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 798 | 471-482 | Disease | denotes | lung lesion | MESH:D008171 |
| 799 | 560-566 | Disease | denotes | deaths | MESH:D003643 |
| 808 | 855-858 | Gene | denotes | IL6 | Gene:3569 |
| 809 | 667-675 | Species | denotes | patients | Tax:9606 |
| 810 | 764-772 | Species | denotes | patients | Tax:9606 |
| 811 | 642-653 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 812 | 733-744 | Chemical | denotes | Tocilizumab | MESH:C502936 |
| 813 | 701-709 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 814 | 778-786 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 815 | 813-831 | Disease | denotes | hyper inflammation | MESH:D007249 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T163 | 40-44 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
| T164 | 427-437 | Body_part | denotes | lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
| T165 | 471-475 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
| T166 | 870-878 | Body_part | denotes | platelet | http://purl.org/sig/ont/fma/fma62851 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T22 | 40-44 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
| T23 | 471-475 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T175 | 45-51 | Disease | denotes | injury | http://purl.obolibrary.org/obo/MONDO_0021178 |
| T176 | 89-97 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T177 | 134-142 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T178 | 701-709 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T179 | 778-786 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T180 | 819-831 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T265 | 40-44 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
| T266 | 40-44 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
| T267 | 112-114 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
| T268 | 263-264 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T269 | 297-299 | http://purl.obolibrary.org/obo/CLO_0008426 | denotes | pg |
| T270 | 471-475 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
| T271 | 471-475 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T171 | 310-321 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T172 | 387-393 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
| T173 | 581-592 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T174 | 642-653 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
LitCovid-sample-MedDRA
| Id | Subject | Object | Predicate | Lexical cue | meddra_id |
|---|---|---|---|---|---|
| T22 | 387-422 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | oxygen saturation and normalization | http://purl.bioontology.org/ontology/MEDDRA/10033322 |
| T23 | 870-885 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | platelet counts | http://purl.bioontology.org/ontology/MEDDRA/10035525 |
LitCovid-sample-PD-IDO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T102 | 363-371 | http://purl.obolibrary.org/obo/OGMS_0000020 | denotes | symptoms |
LitCovid-sample-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T110 | 387-393 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
LitCovid-sample-PD-NCBITaxon
| Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
|---|---|---|---|---|---|
| T217 | 89-97 | Species | denotes | COVID-19 | NCBItxid:2697049 |
| T218 | 134-142 | Species | denotes | COVID-19 | NCBItxid:2697049 |
| T219 | 701-709 | Species | denotes | COVID-19 | NCBItxid:2697049 |
| T220 | 778-786 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T181 | 0-17 | Sentence | denotes | 6.2.2 Rationale: |
| T182 | 18-97 | Sentence | denotes | Tocilizumab can treat lung injury in patients with critical and severe COVID-19 |
| T183 | 98-245 | Sentence | denotes | In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. |
| T184 | 246-464 | Sentence | denotes | Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. |
| T185 | 465-523 | Sentence | denotes | Also, lung lesion opacity was absorbed in 90% of patients. |
| T186 | 524-603 | Sentence | denotes | Neither serious adverse effects nor deaths occurred with tocilizumab treatment. |
| T187 | 604-710 | Sentence | denotes | There are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. |
| T188 | 711-926 | Sentence | denotes | Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]. |
LitCovid-sample-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T22 | 40-44 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
| T23 | 471-475 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 773 | 18-29 | Chemical | denotes | Tocilizumab | MESH:C502936 |
| 774 | 40-51 | Disease | denotes | lung injury | MESH:D055370 |
| 772 | 55-63 | Species | denotes | patients | Tax:9606 |
| 775 | 89-97 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 790 | 120-128 | Species | denotes | patients | Tax:9606 |
| 797 | 134-142 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 793 | 211-222 | Chemical | denotes | Tocilizumab | MESH:C502936 |
| 791 | 246-254 | Species | denotes | Patients | Tax:9606 |
| 788 | 270-273 | Gene | denotes | IL6 | Gene:3569 |
| 794 | 310-321 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 795 | 387-393 | Chemical | denotes | oxygen | MESH:D010100 |
| 789 | 453-456 | Gene | denotes | CRP | Gene:1401 |
| 798 | 471-482 | Disease | denotes | lung lesion | MESH:D008171 |
| 792 | 514-522 | Species | denotes | patients | Tax:9606 |
| 799 | 560-566 | Disease | denotes | deaths | MESH:D003643 |
| 796 | 581-592 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 811 | 642-653 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 809 | 667-675 | Species | denotes | patients | Tax:9606 |
| 813 | 701-709 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 812 | 733-744 | Chemical | denotes | Tocilizumab | MESH:C502936 |
| 810 | 764-772 | Species | denotes | patients | Tax:9606 |
| 814 | 778-786 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 815 | 813-831 | Disease | denotes | hyper inflammation | MESH:D007249 |
| 808 | 855-858 | Gene | denotes | IL6 | Gene:3569 |
LitCovid-sample-UniProt
| Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
|---|---|---|---|---|---|
| T2161 | 270-273 | Protein | denotes | IL6 | https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0 |
| T2205 | 453-456 | Protein | denotes | CRP | https://www.uniprot.org/uniprot/Q5U0J2|https://www.uniprot.org/uniprot/Q07203|https://www.uniprot.org/uniprot/Q01687|https://www.uniprot.org/uniprot/P97315|https://www.uniprot.org/uniprot/P67967|https://www.uniprot.org/uniprot/P67966|https://www.uniprot.org/uniprot/P47875|https://www.uniprot.org/uniprot/P32965|https://www.uniprot.org/uniprot/P21291|https://www.uniprot.org/uniprot/P08462|https://www.uniprot.org/uniprot/A8K268 |
| T2216 | 855-858 | Protein | denotes | IL6 | https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0 |
| T2260 | 860-868 | Protein | denotes | ferritin | https://www.uniprot.org/uniprot/Q26061 |
LitCovid-sample-Enju
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T41884 | 0-5 | CD | denotes | 6.2.2 |
| T3706 | 7-16 | NNP | denotes | Rationale |
| T87509 | 16-17 | -COLON- | denotes | : |
| T72411 | 18-29 | NNP | denotes | Tocilizumab |
| T46139 | 30-33 | MD | denotes | can |
| T80638 | 34-39 | VB | denotes | treat |
| T14365 | 40-44 | NN | denotes | lung |
| T88114 | 45-51 | NN | denotes | injury |
| T76208 | 52-54 | IN | denotes | in |
| T24628 | 55-63 | NNS | denotes | patients |
| T15777 | 64-68 | IN | denotes | with |
| T58130 | 69-77 | JJ | denotes | critical |
| T31522 | 78-81 | CC | denotes | and |
| T55163 | 82-88 | JJ | denotes | severe |
| T92225 | 89-97 | NN | denotes | COVID-19 |
| T21073 | 98-100 | IN | denotes | In |
| T65150 | 101-104 | DT | denotes | the |
| T61991 | 105-110 | NN | denotes | study |
| T18474 | 111-112 | -LRB- | denotes | [ |
| T8341 | 112-114 | CD | denotes | 27 |
| T6430 | 114-115 | -RRB- | denotes | ] |
| T29393 | 115-116 | -COMMA- | denotes | , |
| T77821 | 117-119 | CD | denotes | 21 |
| T79215 | 120-128 | NNS | denotes | patients |
| T5404 | 129-133 | IN | denotes | with |
| T75582 | 134-142 | NN | denotes | COVID-19 |
| T89299 | 143-148 | WP-DOLLAR- | denotes | whose |
| T66055 | 149-158 | NN | denotes | condition |
| T80340 | 159-162 | VBD | denotes | was |
| T3490 | 163-169 | JJ | denotes | severe |
| T44653 | 170-172 | CC | denotes | or |
| T55941 | 173-181 | JJ | denotes | critical |
| T85453 | 182-190 | VBD | denotes | received |
| T98598 | 191-194 | CD | denotes | one |
| T96881 | 195-197 | CC | denotes | or |
| T24534 | 198-201 | CD | denotes | two |
| T70238 | 202-207 | NNS | denotes | doses |
| T20616 | 208-210 | IN | denotes | of |
| T68912 | 211-222 | NNP | denotes | Tocilizumab |
| T98192 | 223-227 | CC | denotes | plus |
| T20706 | 228-236 | JJ | denotes | standard |
| T58005 | 237-244 | NN | denotes | therapy |
| T96625 | 246-254 | NNS | denotes | Patients |
| T75572 | 255-258 | WP | denotes | who |
| T31917 | 259-262 | VBD | denotes | had |
| T15301 | 263-264 | DT | denotes | a |
| T24848 | 265-269 | JJ | denotes | mean |
| T84688 | 270-273 | NN | denotes | IL6 |
| T96963 | 274-279 | NN | denotes | level |
| T6930 | 280-282 | IN | denotes | of |
| T90933 | 283-287 | JJR | denotes | more |
| T81944 | 288-292 | IN | denotes | than |
| T75581 | 293-302 | NN | denotes | 100 pg/ml |
| T64021 | 303-309 | IN | denotes | before |
| T9387 | 310-321 | NN | denotes | tocilizumab |
| T84664 | 322-331 | NN | denotes | treatment |
| T18203 | 332-338 | VBD | denotes | showed |
| T60803 | 339-350 | NN | denotes | improvement |
| T44490 | 351-353 | IN | denotes | in |
| T81402 | 354-362 | JJ | denotes | clinical |
| T14228 | 363-371 | NNS | denotes | symptoms |
| T94537 | 372-375 | CC | denotes | and |
| T83697 | 376-386 | JJ | denotes | peripheral |
| T13978 | 387-393 | NN | denotes | oxygen |
| T35808 | 394-404 | NN | denotes | saturation |
| T34900 | 405-408 | CC | denotes | and |
| T75964 | 409-422 | NN | denotes | normalization |
| T84268 | 423-426 | IN | denotes | for |
| T65028 | 427-437 | NN | denotes | lymphocyte |
| T34390 | 438-448 | NN | denotes | proportion |
| T96610 | 449-452 | CC | denotes | and |
| T30755 | 453-456 | NN | denotes | CRP |
| T63070 | 457-463 | NNS | denotes | levels |
| T31791 | 465-469 | RB | denotes | Also |
| T31152 | 469-470 | -COMMA- | denotes | , |
| T79595 | 471-475 | NN | denotes | lung |
| T51431 | 476-482 | NN | denotes | lesion |
| T10130 | 483-490 | NN | denotes | opacity |
| T31388 | 491-494 | VBD | denotes | was |
| T1824 | 495-503 | VBN | denotes | absorbed |
| T60055 | 504-506 | IN | denotes | in |
| T38598 | 507-509 | CD | denotes | 90 |
| T67288 | 509-510 | NN | denotes | % |
| T48683 | 511-513 | IN | denotes | of |
| T41529 | 514-522 | NNS | denotes | patients |
| T69670 | 524-531 | CC | denotes | Neither |
| T9277 | 532-539 | JJ | denotes | serious |
| T15021 | 540-547 | JJ | denotes | adverse |
| T23626 | 548-555 | NNS | denotes | effects |
| T98539 | 556-559 | CC | denotes | nor |
| T65699 | 560-566 | NNS | denotes | deaths |
| T50204 | 567-575 | VBD | denotes | occurred |
| T20973 | 576-580 | IN | denotes | with |
| T14012 | 581-592 | NN | denotes | tocilizumab |
| T66286 | 593-602 | NN | denotes | treatment |
| T24269 | 604-609 | EX | denotes | There |
| T26765 | 610-613 | VBP | denotes | are |
| T84711 | 614-621 | VBG | denotes | ongoing |
| T74304 | 622-630 | JJ | denotes | clinical |
| T68003 | 631-637 | NNS | denotes | trials |
| T5000 | 638-641 | IN | denotes | for |
| T64198 | 642-653 | NN | denotes | tocilizumab |
| T83078 | 654-663 | NN | denotes | treatment |
| T11331 | 664-666 | IN | denotes | in |
| T42834 | 667-675 | NNS | denotes | patients |
| T27205 | 676-680 | IN | denotes | with |
| T23786 | 681-689 | JJ | denotes | moderate |
| T45333 | 690-693 | CC | denotes | and |
| T9137 | 694-700 | JJ | denotes | severe |
| T27842 | 701-709 | NN | denotes | COVID-19 |
| T92236 | 711-720 | RB | denotes | Currently |
| T32112 | 720-721 | -COMMA- | denotes | , |
| T54987 | 722-725 | DT | denotes | the |
| T85855 | 726-729 | NN | denotes | use |
| T69355 | 730-732 | IN | denotes | of |
| T40115 | 733-744 | NNP | denotes | Tocilizumab |
| T10850 | 745-747 | VBZ | denotes | is |
| T78367 | 748-759 | VBN | denotes | recommended |
| T33042 | 760-763 | IN | denotes | for |
| T36466 | 764-772 | NNS | denotes | patients |
| T61983 | 773-777 | IN | denotes | with |
| T2749 | 778-786 | NN | denotes | COVID-19 |
| T17580 | 787-790 | WP | denotes | who |
| T69055 | 791-795 | VBP | denotes | have |
| T71996 | 796-803 | VBG | denotes | warning |
| T59356 | 804-809 | NNS | denotes | signs |
| T65527 | 810-812 | IN | denotes | of |
| T99769 | 813-818 | NN | denotes | hyper |
| T44301 | 819-831 | NN | denotes | inflammation |
| T54453 | 831-832 | -COMMA- | denotes | , |
| T58078 | 833-835 | IN | denotes | as |
| T75237 | 836-839 | MD | denotes | can |
| T7496 | 840-842 | VB | denotes | be |
| T53845 | 843-851 | VBN | denotes | measured |
| T78207 | 852-854 | IN | denotes | by |
| T88455 | 855-858 | NN | denotes | IL6 |
| T77671 | 858-859 | -COMMA- | denotes | , |
| T67481 | 860-868 | NN | denotes | ferritin |
| T99390 | 868-869 | -COMMA- | denotes | , |
| T23484 | 870-878 | NN | denotes | platelet |
| T65701 | 879-885 | NNS | denotes | counts |
| T30323 | 885-886 | -COMMA- | denotes | , |
| T72053 | 887-899 | JJ | denotes | inflammatory |
| T81575 | 900-907 | NNS | denotes | markers |
| T96428 | 907-908 | -COMMA- | denotes | , |
| T36542 | 909-912 | CC | denotes | and |
| T88469 | 913-914 | NN | denotes | H |
| T51141 | 915-920 | NN | denotes | score |
| T97739 | 921-922 | -LRB- | denotes | [ |
| T29313 | 922-924 | CD | denotes | 28 |
| T54016 | 924-925 | -RRB- | denotes | ] |
| R9002 | T3706 | T41884 | arg1Of | Rationale,6.2.2 |
| R84332 | T3706 | T87509 | arg1Of | Rationale,: |
| R86004 | T72411 | T46139 | arg1Of | Tocilizumab,can |
| R37530 | T80638 | T46139 | arg2Of | treat,can |
| R92198 | T72411 | T80638 | arg1Of | Tocilizumab,treat |
| R29604 | T88114 | T80638 | arg2Of | injury,treat |
| R90482 | T88114 | T14365 | arg1Of | injury,lung |
| R82985 | T80638 | T76208 | arg1Of | treat,in |
| R69456 | T24628 | T76208 | arg2Of | patients,in |
| R21368 | T24628 | T15777 | arg1Of | patients,with |
| R79687 | T92225 | T15777 | arg2Of | COVID-19,with |
| R76769 | T92225 | T58130 | arg1Of | COVID-19,critical |
| R76550 | T58130 | T31522 | arg1Of | critical,and |
| R20598 | T55163 | T31522 | arg2Of | severe,and |
| R4477 | T92225 | T55163 | arg1Of | COVID-19,severe |
| R75326 | T85453 | T21073 | arg1Of | received,In |
| R27739 | T61991 | T21073 | arg2Of | study,In |
| R82994 | T61991 | T65150 | arg1Of | study,the |
| R48681 | T61991 | T18474 | arg1Of | study,[ |
| R80450 | T8341 | T18474 | arg2Of | 27,[ |
| R99891 | T6430 | T18474 | arg3Of | ],[ |
| R98220 | T85453 | T29393 | arg1Of | received,"," |
| R79228 | T79215 | T77821 | arg1Of | patients,21 |
| R3039 | T79215 | T5404 | arg1Of | patients,with |
| R31375 | T75582 | T5404 | arg2Of | COVID-19,with |
| R14004 | T66055 | T89299 | arg1Of | condition,whose |
| R84172 | T75582 | T89299 | arg2Of | COVID-19,whose |
| R52999 | T66055 | T80340 | arg1Of | condition,was |
| R29264 | T44653 | T80340 | arg2Of | or,was |
| R90654 | T66055 | T3490 | arg1Of | condition,severe |
| R25403 | T3490 | T44653 | arg1Of | severe,or |
| R81194 | T55941 | T44653 | arg2Of | critical,or |
| R78022 | T66055 | T55941 | arg1Of | condition,critical |
| R74963 | T79215 | T85453 | arg1Of | patients,received |
| R42123 | T70238 | T85453 | arg2Of | doses,received |
| R67132 | T70238 | T98598 | arg1Of | doses,one |
| R74424 | T98598 | T96881 | arg1Of | one,or |
| R53734 | T24534 | T96881 | arg2Of | two,or |
| R5731 | T70238 | T24534 | arg1Of | doses,two |
| R65601 | T70238 | T20616 | arg1Of | doses,of |
| R56743 | T98192 | T20616 | arg2Of | plus,of |
| R89899 | T68912 | T98192 | arg1Of | Tocilizumab,plus |
| R61440 | T58005 | T98192 | arg2Of | therapy,plus |
| R97353 | T58005 | T20706 | arg1Of | therapy,standard |
| R37793 | T96625 | T75572 | arg1Of | Patients,who |
| R91228 | T96625 | T31917 | arg1Of | Patients,had |
| R53068 | T96963 | T31917 | arg2Of | level,had |
| R75826 | T96963 | T15301 | arg1Of | level,a |
| R53187 | T96963 | T24848 | arg1Of | level,mean |
| R88261 | T96963 | T84688 | arg1Of | level,IL6 |
| R96088 | T96963 | T6930 | arg1Of | level,of |
| R5373 | T90933 | T6930 | arg2Of | more,of |
| R57258 | T90933 | T81944 | arg1Of | more,than |
| R94369 | T75581 | T81944 | arg2Of | 100 pg/ml,than |
| R45661 | T90933 | T64021 | arg1Of | more,before |
| R79916 | T84664 | T64021 | arg2Of | treatment,before |
| R78642 | T84664 | T9387 | arg1Of | treatment,tocilizumab |
| R8185 | T96625 | T18203 | arg1Of | Patients,showed |
| R51850 | T94537 | T18203 | arg2Of | and,showed |
| R12091 | T60803 | T44490 | arg1Of | improvement,in |
| R66809 | T14228 | T44490 | arg2Of | symptoms,in |
| R61551 | T14228 | T81402 | arg1Of | symptoms,clinical |
| R5554 | T60803 | T94537 | arg1Of | improvement,and |
| R21619 | T34900 | T94537 | arg2Of | and,and |
| R92393 | T35808 | T83697 | arg1Of | saturation,peripheral |
| R24887 | T35808 | T13978 | arg1Of | saturation,oxygen |
| R90774 | T35808 | T34900 | arg1Of | saturation,and |
| R67692 | T75964 | T34900 | arg2Of | normalization,and |
| R62752 | T34900 | T84268 | arg1Of | and,for |
| R8244 | T63070 | T84268 | arg2Of | levels,for |
| R10896 | T63070 | T65028 | arg1Of | levels,lymphocyte |
| R57903 | T63070 | T34390 | arg1Of | levels,proportion |
| R97168 | T34390 | T96610 | arg1Of | proportion,and |
| R13130 | T30755 | T96610 | arg2Of | CRP,and |
| R88299 | T63070 | T30755 | arg1Of | levels,CRP |
| R81985 | T1824 | T31791 | arg1Of | absorbed,Also |
| R90910 | T1824 | T31152 | arg1Of | absorbed,"," |
| R99138 | T10130 | T79595 | arg1Of | opacity,lung |
| R9904 | T10130 | T51431 | arg1Of | opacity,lesion |
| R90450 | T10130 | T31388 | arg1Of | opacity,was |
| R27294 | T1824 | T31388 | arg2Of | absorbed,was |
| R44975 | T10130 | T1824 | arg2Of | opacity,absorbed |
| R49421 | T1824 | T60055 | arg1Of | absorbed,in |
| R89954 | T67288 | T60055 | arg2Of | %,in |
| R85705 | T67288 | T38598 | arg1Of | %,90 |
| R91084 | T67288 | T48683 | arg1Of | %,of |
| R76104 | T41529 | T48683 | arg2Of | patients,of |
| R22449 | T98539 | T69670 | arg1Of | nor,Neither |
| R42879 | T98539 | T9277 | arg1Of | nor,serious |
| R85183 | T98539 | T15021 | arg1Of | nor,adverse |
| R27191 | T23626 | T98539 | arg1Of | effects,nor |
| R64318 | T65699 | T98539 | arg2Of | deaths,nor |
| R37231 | T98539 | T50204 | arg1Of | nor,occurred |
| R56159 | T50204 | T20973 | arg1Of | occurred,with |
| R79941 | T66286 | T20973 | arg2Of | treatment,with |
| R50965 | T66286 | T14012 | arg1Of | treatment,tocilizumab |
| R66954 | T24269 | T26765 | arg1Of | There,are |
| R94262 | T68003 | T26765 | arg2Of | trials,are |
| R16905 | T68003 | T84711 | arg1Of | trials,ongoing |
| R34037 | T68003 | T74304 | arg1Of | trials,clinical |
| R29518 | T68003 | T5000 | arg1Of | trials,for |
| R26554 | T83078 | T5000 | arg2Of | treatment,for |
| R27449 | T83078 | T64198 | arg1Of | treatment,tocilizumab |
| R95470 | T83078 | T11331 | arg1Of | treatment,in |
| R78533 | T42834 | T11331 | arg2Of | patients,in |
| R30062 | T42834 | T27205 | arg1Of | patients,with |
| R17601 | T27842 | T27205 | arg2Of | COVID-19,with |
| R89241 | T27842 | T23786 | arg1Of | COVID-19,moderate |
| R28465 | T23786 | T45333 | arg1Of | moderate,and |
| R59576 | T9137 | T45333 | arg2Of | severe,and |
| R97104 | T27842 | T9137 | arg1Of | COVID-19,severe |
| R53041 | T58078 | T92236 | arg1Of | as,Currently |
| R61441 | T58078 | T32112 | arg1Of | as,"," |
| R66943 | T85855 | T54987 | arg1Of | use,the |
| R89881 | T85855 | T69355 | arg1Of | use,of |
| R92489 | T40115 | T69355 | arg2Of | Tocilizumab,of |
| R4907 | T85855 | T10850 | arg1Of | use,is |
| R54223 | T78367 | T10850 | arg2Of | recommended,is |
| R26904 | T85855 | T78367 | arg2Of | use,recommended |
| R93944 | T78367 | T33042 | arg1Of | recommended,for |
| R96954 | T36466 | T33042 | arg2Of | patients,for |
| R92720 | T36466 | T61983 | arg1Of | patients,with |
| R61251 | T2749 | T61983 | arg2Of | COVID-19,with |
| R60119 | T36466 | T17580 | arg1Of | patients,who |
| R35135 | T36466 | T69055 | arg1Of | patients,have |
| R48731 | T59356 | T69055 | arg2Of | signs,have |
| R72772 | T59356 | T71996 | arg1Of | signs,warning |
| R6154 | T59356 | T65527 | arg1Of | signs,of |
| R22400 | T44301 | T65527 | arg2Of | inflammation,of |
| R13264 | T44301 | T99769 | arg1Of | inflammation,hyper |
| R72983 | T78367 | T54453 | arg1Of | recommended,"," |
| R85482 | T78367 | T58078 | arg1Of | recommended,as |
| R94310 | T53845 | T58078 | arg2Of | measured,as |
| R71674 | T85855 | T75237 | arg1Of | use,can |
| R96842 | T53845 | T75237 | arg2Of | measured,can |
| R13154 | T85855 | T7496 | arg1Of | use,be |
| R84932 | T53845 | T7496 | arg2Of | measured,be |
| R87538 | T85855 | T53845 | arg2Of | use,measured |
| R19206 | T53845 | T78207 | arg1Of | measured,by |
| R40933 | T36542 | T78207 | arg2Of | and,by |
| R89076 | T88455 | T77671 | arg1Of | IL6,"," |
| R2282 | T67481 | T77671 | arg2Of | ferritin,"," |
| R15531 | T77671 | T99390 | arg1Of | ",","," |
| R60586 | T65701 | T99390 | arg2Of | counts,"," |
| R8993 | T65701 | T23484 | arg1Of | counts,platelet |
| R92565 | T99390 | T30323 | arg1Of | ",","," |
| R21977 | T81575 | T30323 | arg2Of | markers,"," |
| R92122 | T81575 | T72053 | arg1Of | markers,inflammatory |
| R15083 | T36542 | T96428 | arg1Of | and,"," |
| R68271 | T30323 | T36542 | arg1Of | ",",and |
| R27501 | T51141 | T36542 | arg2Of | score,and |
| R83390 | T51141 | T88469 | arg1Of | score,H |
| R41615 | T51141 | T97739 | arg1Of | score,[ |
| R59110 | T29313 | T97739 | arg2Of | 28,[ |
| R77316 | T54016 | T97739 | arg3Of | ],[ |
LitCovid-sample-PD-MAT
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T6 | 40-44 | http://purl.obolibrary.org/obo/MAT_0000135 | denotes | lung |
| T7 | 471-475 | http://purl.obolibrary.org/obo/MAT_0000135 | denotes | lung |
LitCovid-sample-PD-GO-BP-0
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T32 | 819-831 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
LitCovid-sample-PD-FMA
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T163 | 40-44 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
| T164 | 427-437 | Body_part | denotes | lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
| T165 | 471-475 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
| T166 | 870-878 | Body_part | denotes | platelet | http://purl.org/sig/ont/fma/fma62851 |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T165 | 45-51 | Disease | denotes | injury | http://purl.obolibrary.org/obo/MONDO_0021178 |
| T166 | 89-97 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T167 | 134-142 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T168 | 701-709 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T169 | 778-786 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T170 | 819-831 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
LitCovid-sample-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T28 | 819-831 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T28 | 819-831 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T181 | 0-17 | Sentence | denotes | 6.2.2 Rationale: |
| T182 | 18-97 | Sentence | denotes | Tocilizumab can treat lung injury in patients with critical and severe COVID-19 |
| T183 | 98-245 | Sentence | denotes | In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. |
| T184 | 246-464 | Sentence | denotes | Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. |
| T185 | 465-523 | Sentence | denotes | Also, lung lesion opacity was absorbed in 90% of patients. |
| T186 | 524-603 | Sentence | denotes | Neither serious adverse effects nor deaths occurred with tocilizumab treatment. |
| T187 | 604-710 | Sentence | denotes | There are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. |
| T188 | 711-926 | Sentence | denotes | Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]. |